"Cambodia Pharmaceuticals & Healthcare Report Q2 2015" is now available at Fast Market Research

Access to healthcare and financial sustainability are two key challenges that will weigh on the effectiveness of Cambodia's universal healthcare programme. Expected to be implemented by 2025, the scheme will provide revenue earning opportunities to pharmaceutical firms with generic drug portfolios.

Headline Expenditure Projections

* Pharmaceuticals: KHR821.7bn (USD204mn) in 2013 to KHR910.8bn (USD228mn) in 2014; +10.8% in local currency terms and +11.4% in US dollar terms. Forecast slightly upgraded from previous quarter.
* Healthcare: KHR3,260.6bn (USD810mn) in 2013 to KHR3,469.7bn (USD870mn) in 2014; +6.4% in local currency terms and +6.9% in US dollar terms. Forecast unchanged from previous quarter.

Risk/Reward Index

Cambodia's Pharmaceutical Risk/Reward Index (RRI) score for Q115 is 32.4 out of the maximum 100. The country scored below average for almost all indicators and sub-indicators including overall market expenditure, sector value growth and pensionable population. Consequently, with this low score, Cambodia ranks second-to-last out of the 19 key markets in Asia Pacific, ahead of Myanmar.

Full Report Details at
- http://www.fastmr.com/prod/977522_cambodia_pharmaceuticals_healthcare_report_q2.aspx?afid=301

Key Trends And Developments

* In December 2014, the Cambodian authorities announced plans to implement a universal healthcare programme as part of the country's 10-year National Social Protection Strategy. Projected to be in place by 2025, the scheme will be a significant improvement on current forms of coverage, including the Community Based Health Insurance scheme - which targets workers in the informal sector.
* In the same month, authorities confirmed that there were more than 100 HIV positive patients in a remote village, Roka in Cambodia. Prime Minister Hu Sen called for an investigation, as the mass infection was allegedly spread by contaminated needles used in medical treatment by an unlicensed healthcare worker.

BMI Economic View: Cambodia has registered impressive real GDP growth over recent years, with growth driven largely by low-end...

The Cambodia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Cambodia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Cambodia pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Cambodia, to test other views - a key input for successful budgeting and strategic business planning in the Cambodian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bulgaria Pharmaceuticals & Healthcare Report Q2 2015
- South Korea Pharmaceuticals & Healthcare Report Q2 2015
- Peru Pharmaceuticals & Healthcare Report Q2 2015
- Nigeria Pharmaceuticals & Healthcare Report Q2 2015
- Mexico Pharmaceuticals & Healthcare Report Q2 2015